Introduction
The dengue viruses ( DENVs). comprised of four distinct scrorypcs, DENVs 1. 2, 3. and 4. in the fami ly Flaviviridac. arc transmitted to humans by Aedes aegypli mosquitoes result ing in an esti mated I 00 million infections annually in the tropics and subtropics (Monath. 1986) . Most dengue infections are asymptomatic or result in uncomplicated dengue fever (DF). a mild to moderate acute febrile illness. Because immuniry foll owing infection is serotype specific. individuals remain at risk fo r seco ndary infection from other serotypes. A small but significant number of individuals develop dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS ). wh ich arc severe. sometimes life-th reatening illnesses. The ri sk for DHF and DSS is greater fo llowing a second dengue infection (Halstead. 1988) , although the pathogenesis is not fully understood. While sc rorypc-specific virus neutralizi ng antibod ies directed against the virion envelope (E) antigen are associated with protection (Kaufman et al.. 1987) . non-neutralizing, cross-reactive antibod ies appear to mediate the infection of Fe receptor bearing cells, e.g .. monocytes and macrophages. leading to higher viremia and more severe disease (Halstead, 1988 ) underscoring the need fo r a vaccine that protects against all four DENV serotypes.
Most recent efforts to develop a dengue vaccine have focused on live attenuated viruses (LAVs ) (Bhamara pravati, Yoksan. 1997 ).
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However, the safery and efficacy of these products has yet to be demonstrated (Sabcharcon et al., 2002) . Unpredictable interactions among the four virus serorypes in tetravalent LAV (TLAV) formulations have historically made it difficult to achieve a vaccine that is both satisfactorily attenuated and highly immunogenic. This was demonstrated by significa nt de ngue-l ike ill ness seen in clinical trials of one candidate dengue TLAV vaccine where an undcr-artenuated DENV 3 component in the tetravale nt formulation was the apparent cause of the reactogenicity (l<itchcner et al.. 2006) . which effectively halted the further clinical development of tha t product.
Three otherTLAV vaccine candidates are currently in cl inical trials. One of these vaccines is attenuated by serial passage of wild-type viruses in POl< cells fo llowed by production in fetal rhesus lung (FRill) diploid cells (Hillstc,lcl and Marchctte. 2003; Eckels ct al.. 2003 : Sun er al.. 2003 Sun cr al., 2009) . The other two arc gcnericdlly engineered chimeras, with the dengue structural genes expressed from an infectious clone of yellow fever virus 170 vaccine (Guirak hoo er al., 2006) , or an infectious clone of DENV 4 containing attenuating mutations in d1e 3' non-coding region of the viral genome (McArthur et al.. 2008 : Durbin et al.. 2006a . produced in Vera cells. Wl1ile all three of these products have good safet y profiles. it has proven difficult to achieve tetravalent virus neutralizi ng anri body responses afte r one close of vilccine. possibly because som e virus serotypes replicate more efficiently so as to be domina nt over or interfere with other serotypes in the tetravalent mixture. Evidence for cross se rorype interference can also be seen in rhesus monkeys (Guy et al.. 2009 ). An earlier monovalent DENV 2 U\V vacci ne candidate was also found to be more immunogenic in yellow fever immune subjects (Scott el al.. 1983 ) , probably due to increased vaccine viremia (Bancroft et al .. 1981 ) . This suggests that immunological priming, even with heterologous antigen, can significantly alter the host's immune responses to DEN U\V vaccines. In addition to the TU\V vacci nes currently in advanced clinical trials, there are other DENV vacci ne candidates in earlier stages of testi ng, includ ing a chimeric U\V vaccine in an attenuated DENV 2 background (Huang et al.. 2003 ) , a purified inactivated whole virus {PIV) vaccine (Putnak et al.. 2005) , a recombinant subunit vaccine based on the aminoterminal80% ofE protein (Putnak et al., 2005) . a recombinant subunit vaccine based on E domain III (Simmons et al.. 2001 ) , and a DNA vaccine expressing the prME structural gene region (Simmons et al .. 200 1 ) . One advantage of non-replicating vaccines is that they might immunize more quickly and exhibit less serotype domi nance or interference than LAV vaccines, although some might be less effective at eliciting cell-mediated immune responses and at conferring long-term immunity. Alternatively, it might be possible to use some combination of live and non-replicating vaccines to achieve a more balanced immune response in a shorter period of time. The idea of primi ng and boosting with different vaccines has previously been tested experimentally for immunizing against HIV (Barnett et al.. 1997 ) and malaria (Sedegah et al .. 1998) .
In the present study, we tested a prime boost approach for dengue in rhesus macaques by priming the ani mals with either TPIV or TDNA vaccines followed by boosting with a TLAV vaccine. The vaccinated animals were then challenged with near wild-type strains of DENV to determine if they were protected. Although dengue infection in the rhesus model is clinically inapparent, dengue non-immune animals become viremic when challenged: therefore. in this model viremia serves as a surrogate for human infection. and as a way fo r measuring the protective efficacy of DENV vaccine candidates (Sun et al., 2006) . We found that animals primed wi th non-replicating vaccines developed mainly low titered virus neutralizing antibodies and also non-neutralizi ng antibodies. which could be measured by ELISA. After boosti ng with the TLAV vaccine, the animals exhibited a secondary type immune response with higher titered and more broadly cross serotype-reactive neutralizing antibodies than were seen after priming or after a si ngle dose ofTLAV vaccine. Animals that received the TPIV / TLAV pri me boost vaccine were completely protected against viremia after virus challenge. These results suggest that a prime boost vaccination strategy might be effective for protecting humans against dengue.
Results
Non-replicating tetravalent DENV vacci nes primed rhesus macaques for an immune response to a tetravalent live attenuated virus (TLAV) vaccine.
An initial experiment was performed in 16 navivirus na' ive rhesus macaques to determine the most effective priming vaccine, dengue tetravalent DNA (TDNA) or tetravalent PIV (TPIV) vaccine. Animals were randomly assigned to one of four groups with each group containing 4 animals, and inoculated with either two doses ofTDNA vaccine (Group 1 ), one dose of TPIV vaccine (Group 2), or for comparison, with one dose ofT U\V vacci ne (Group 3). An unvaccinated control group received phosphate-buffered saline only (G roup 4). Two months later, all animals except the saline controls were boosted with one dose of the TU\V vaccine. Measurement of virus neutralizing (N) and total antibody titers against all four DENV serotypes after vaccination and measurement of serum viremia after monovalent challenge with a near wild-type strain of DENV 3 were used to evaluate the more effective prime boost vaccine combination.
Antibody responses to vaccination
After primary vaccination, all groups except the saline control made antibodies to all four DENV serotypes measured by ELISA (data not shown ) and virus plaque reduction neutralization test (PRNT50 ) (Fig. 1 ) and remained positive fo r virus N antibod ies 30 and 60 days after primary vaccination. The N antibody geometric mean titers (GMTs) for serotype 2 were higher than fo r the other serotypes. After boosting with the TLA V vaccine. the N antibody GMTs for all serotypes increased in all groups. reaching a peak 1 month later, at which time the highest N antibody GMTs were against DENV 2 and DENV 4. TheN antibody titers then declined sharply ove r the nex t 2 months ,1nd more gradually thereafter until administration of the challenge virus at month 8. On the day of challenge, all groups remai ned antibody positive. with Group 2 (W IV /TLAV ) exhibi ting the highest total and N antibody titers and w ith the highest N antibody titers being against DENV 2.
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Responses co monovalent wild-type DENV 3 clwlleuge
To assess protection. a near wi ld-type isolate of DENV 3 was chosen because the lowest virus N antibody titers in all groups were against serotype 3. The DENV 3 challenge virus was .1dministered to all animals including the sal ine controls. and sera were collected for 10 consecutive days for me,1suring viremia. The post-challenge viremia results are shown in Table I ( Fig. 1 ). Based on these results, a second experiment was performed to determine whether priming with a TPIV vaccine followed by boosting with a Tl.AV vaccine can con fer protection aga inst all four DENV scrotypes.
DEN TPIV and DEN TI.AV vaccines used in a prime boost vaccine combinarion protected riles us macaq11es against cllal/enge witil all Jo11r DENV serotypes
For this experiment. 32 navivirus na· ive animals were randomly assigned to two cohorts of 16 animals each. The fi rst cohor t was vaccinated wi th TPIV vaccine followed 2 months later by TLAV 
A11tibody responses after vacci11ation with TPIV and boosting witlr TI.A V vacci11e
The resu lts i n Fig. 3 show that after primary vaccination w ith TPIV. all animals had N antibodies to all four DENV scrotypes. Although the GMTs were low they were si milar for all serotypes.
Viremia in rhesus macaques immunized wilh combinalions of 1r1rav. 1lent live a11cnua1cd virus (TIAV). rc1ravalen1 purified inaCiivalcd virus (TPIV). and 1e1ravalen1 DNA (TONI\) vaccines and I hen challenged wuh live. non-anenualed DENV 3.
V.1ccine coml>ination
'filled black squares show I he days afler ch.111engc I hal dengue virus was de1ec1ed in ser.1l>y .1mplific.uion in Vera cells followed by de1ec1ion of virus-infecled cells using IF A. TI1e N antibody GMTs then increased after the TL4.V booster vaccination given at month 2 and peaked between study day 90 and day 120, with the highest GMT achieved for DENV 2 (1:6000) and lower GMTs ranging from 1 :500 to 1:1200 for the other serotypes. The GMTs for all serotypes then declined at variable rates, with the steepest decline in titer occurring within one to 2 months after peaking, followed by a more gradual decline to the day of challenge, similar to what was seen in the first experiment On the day of challenge (month 8), theN antibody GMTs were 1:62 for serotype 3, 1: 154 for serotype 1, 1: 174 for serotype 4, and 1 :767 for serotype 2.
Viremia responses after TIAV vaccination and tetravalent wild-type DENV challenge
While priming with TPIV vaccine did lead to better immune responses to the TL4.V vaccine, it did not enhance the replication of any of the vaccine viruses leading to detectable viremia (data not shown). In order to determine if the vaccinated animals were protected against all four DENV serotypes, both vaccinated and control (mock vaccinated) cohorts were challenged with near wildtype challenge viruses, with groups of 4 vaccinated and 4 control animals each receiving a different challenge virus, DENV 1, 2, 3, or 4. The post-challenge viremia results are shown in Table 2 . In the mock (PBS) vaccinated cohort, all animals challenged with each DENV serotype became viremic, thus demonstrating a successful challenge for each serotype. The animals challenged with DENV 4 exhibited the shortest duration of viremia with a mean of 2.75 days, whereas the animals challenged with DENV 1, DENV 2. or DENV 3 exhibited 4 to 5 mean days of viremia, consistent with previous rhesus challenge experiments (Simmons and Putnak, unpublished results) .In contrast, in the vaccinated cohort, there was no detectable viremia with any of the challenge virus serotypes. There were, however, anamnestic antibody responses observed in most vaccinated animals after the virus challenge, with increases in N antibody titers against all serotypes and an increase in total antibody titers against DENV 2. DENV 3, and DENV 4 (Fig. 4 ) .
Discussion
It has proven very difficult and costly to develop tetravalent dengue vaccine candidates that immunize and confer both immediate and long-term immunity to all four virus serotypes with a minimum of vaccine-associated adverse effects. Following primary vaccination of flavivirus naive subjects in clinical trials with some tetravalent live attenuated virus (Tl.AV) vaccine formulations, protective virus neutralizing antibodies against some serotypes are very low or undetectable, suggesting that those serotypes replicate and immunize poorly. In contrast. other virus serotypes appear to dominate the immune response and sometimes cause viremia, which may lead to increased vaccine reactogenicity seen as dengue-like illness (l<itch-ener et at., 2006) . Although a second dose ofTI.AV vaccine generally leads to improved tetravalent seroconversion rates and higher virus neutralizing antibody titers with reduced reactogenicity. it appears that this must be administered 6 months or longer following primary vaccination in order to be most effective. Non-replicating tetravalent dengue vaccines may exhibit less serotype dominance and vaccineassociated adverse effects and allow for the use of shorter time intervals between primary and booster vaccinations. However, such vaccines may not be as effective as TL4.V vaccines at conferring longterm immunity. Therefore, in this study an alternative strategy for vaccinating against dengue was tested in the rhesus macaque animal model. This involved priming the animals with a non-replicating vaccine, either a tetravalent purified inactivated virus (TPIV) or a tetravalent plasmid DNAs expressing the prME structural gene region (TDNA), followed by boosting with a tetravalent live attenuated virus (TIAV} vaccine. The aims of this study were threefold: (i) to demonstrate that priming with a non-replicating vaccine followed by boosting with a TL4. V vaccine is able to elicit high titered virus neutralizing (N) antibodies and confer protection against all four DENV serotypes; (ii) to demonstrate that a heterologous prime boost vaccination strategy has a low risk for eliciting vaccine-related adverse events and might even reduce the risk for reactogenicity by moderating the replication of under-attenuated viruses in a tetravalent L4.V vaccine; and (iii) to demonstrate the feasibility of a compressed immunization schedule (2-3 months vs. 6-7 months}, potentially allowing for more rapid development of protective immunity than can be achieved with existing Tl..A V vaccine candidates. An initial experiment was performed in rhesus macaques to determine whether TPIV or TDNA vaccine was more effective at priming for a booster response to a TI..AV vaccine administered 2 months later. After priming with two doses of TDNA. one dose of TPIV. or one dose ofTI..AV vaccine, the seroconversion rates and virus N antibody titers against each serotype measured by PRNf were comparable among groups, except for much higher DENV 2 N antibody titers in the TI..AV group. Following boosting with the TI..AV vaccine, the kinetics of the anamnestic N antibody response was similar for all groups. The highest N antibody GMTs were against DENV 2 followed by DENVs 4, 1, and 3. Measurement of total DENV 3 lgG titers by EUSA on the day of challenge showed that the TPIV /Tl..A V group had the highest titer followed by the Tl..AV/Tl..AV group, while the TDNA/TDNA/TLAV group had the lowest totallgG titer. Because the DENV 3 N antibody titers were lower than those for the other serotypes in all three immunization regimens. this virus was chosen for the challenge.
After DENV 3 challenge, complete protection against viremia was seen in groups that received the TPIV/Tl..AV and Tl..AV/Tl..AV combinations. Breakthrough viremia was detected in the TDNA/ TDNA/TI..AV group, although it was reduced in duration compared to the mock-vaccinated controls. After the DENV 3 challenge, all groups including the TI..A V /Tl..A V group exhibited anamnestic N antibody increases for all serotypes. Not surprisingly, the greatest increase in N antibody titer after challenge was seen in the TDNA/TDNA/Tl..AV group, with the greatest fold increase in titer and the highest absolute titer against DENV 3. consistent with the breakthrough viremia observed in those animals. It is unclear why the TDNA/TDNA/Tl..AV combination provided incomplete protection from challenge. Priming by TDNA vaccine required two doses vs. one dose for TPIV. It is possible that at least some epitopes important for protection were either nor correctly expressed or presented by this vaccine. Somewhat surprisingly, the best correlate of protection against viremia in this experiment was the total anti-DENV 3 lgG antibody measured by ELISA on the day of challenge, rather than the neutralizing antibody titer.
Based on results from the first experiment, the TPIV / Tl.A V prime boost vaccine combination was tested for the ability to confer protection against viremia after challenge with wild-type strains of all four DENV serotypes. Similar to the first experiment, animals were primed with one dose ofTPIV, boosted with Tl.AV 2 months later, and then challenged at month 8, with fou r an imals receiving each challenge virus serotype. After the administration of the TPIV vaccine. the animals developed low but measurable N antibody titers against each serotype demonstrating successful priming. After the Tl.AV booster, the N antibody titers against each serotype increased more than I 0-fold. indicating strong anamnestic antibody responses. Importantly, after the Tl.AV booster no vaccine-associated viremia was detected for any serotype nor did the animals show any other adverse effects. suggesting that TPIV priming was safe. N antibody titers declined sharply at first and then more gradually to the day of challenge (month 8) at which time the highest N antibody titers were against DENV 2 (1 :767) followed by DENV 4 (1 :174), DENV 1 (1 :154). and DENV 3 (1:62). In comparison, the total DENV lgG titers on the day of challenge were highest fo r DENV 1 and DENV 2, followed by DENV 4 and DENV 3. This difference between N and total antibody titers among serotypes may have been due to the greater serotype cross-reactivity of total lgG antibodies compared with N antibodies. which tend to be more serotype specific. After the virus challenge, there was complete protection against viremia from all four serotypes. There were, however, strong anamnestic N antibody responses to three of the four challenge viruses as shown in Fig. 3 , with approximately 8-to 14-fold increases in N antibody titers for DENVs 3, 4, and I but only about a threefold increase in titer for DENV 2. possibly indicating near sterile immunity to DENV 2. In comparison. total antibody titers. which were higher prior to challenge, did nor increase as much after challenge. with only two-to threefold increases for DENVs 2. 3, and 4 and no measurable increase for DENV 1.
These two experiments clearly demonstrated that rhesus macaques could be successfully immunized and protected against all four DENV serorypes using TPIV vaccine followed by Tl.AV vaccine in a prime boost vaccination strategy. low bur measurable titers of N antibody were elicited against each DENV serotype by primary vaccination with TPIV demonstrating successful priming. However. the presence of these virus N antibodies after priming apparently did nor inhibit replication of the Tl.AV vaccine enough to prevent successful boosting. as evidenced by strong anamnestic N antibody responses following Tl.AV administration. Although it could nor be demonstrated in these experiments. it is possible that low ritered virus neutralizing antibodies may be able to modulate the replication of under-attenuated strains present in Tl.AV vaccine fo rmulations. thereby reducing vaccine reacrogeniciry. It is also notable that nonneutralizing, presumably serotype cross-reactive antibodies generated in response to primary vaccinatio n did not enhance the replication of the attenuated vaccine viruses to the point of viremia.
Although the significance of the immune-dominance of DENV serotype 2 in terms of theN antibody response is unclear. the uniform development of N antibodies against all four DENV serotypes within 1 month after the Tl.AV booster, without evidence for vaccine-induced viremia. further demonstrated that priming with non-replicating vaccine was effective and suggests that protective immunity can be achieved safely and rapidly by heterologous prime boost vaccination. Arguably, however. Tl.AV vaccine alone. when two doses were administered 2 months apart, was also able in a short period of time to elicit moderate to high rirered N antibodies against all four DENV serorypes in the rhesus model. in contrast to the requirement for a longer time interval between doses for effective immunization of humans. This result suggests some shortcomings to the use of rhesus macaques for predicting the outcome of vaccination in humans. Nevertheless. viremia in rhesus macaques is the best animal model for dengue infection currently available, and the results clearly demonstrate that animals vaccinated with TPIV followed by Tl.AV vaccine were completely protected against viremia after challenge 8 months later with near wild-type DENV strains representing each serotype.
The reason for the challenge breakthrough seen in the first experiment with DENV 3 viremia in animals vaccinated with the TDNA/ TDNA/ Tl.AV combination is unclea r. The low DENV 3 N an tibody GMT ( 1 :41 ) at the rime of challenge might have been a plausible explanation except that the Tl.AV / TLAV group had a similarly low DENV 3 GMT ( 1 :47). yet that group was completely protected. Interestingly, the animals in the TDNA/TDNA/Tl.AV group also had rhe lowest total DENV lgG antibody titers at month 8, and there was a correlation between total DENY lgG titers at the rime of challenge and protection against viremia. Therefore. it is possible that non-neutralizing antibodies may also play an important role in protective immunity, perhaps through complement mediated lysis of virus and virus-infected cells. or antibody-dependent cell-mediated cytotoxicity (ADCC), which is difficult to measure in vitro.
In future studies, it wi ll be important to further define the correlates of immunity to DENV as well as test the safety and immunogenicity of heterologous prime boost vaccine approaches in a Phase 1 clinical trial.
Materials and methods
Viruses
Cell culture supernatant harvested from Vero cells infected with DENV 1 (West Pac 74). DENV 2 (S16803 ). DEN 3 (CH53489), and DEN 4 {341750) was used as virus srock for the plaque reduction neutralization test (PRNT) and to prepare antigen for the ELISA
Plaque-reduction neutralization assay
Plaque-reduction neutralization tests (PRNTs) were performed to measure DENV neutralizing antibodies, using a method mod ified from that originally described (Russell er al .. 1967) . Vero cell mono layers were seeded in six-well plates (Falcon; Becton Dickinson, lincoln Park, NJ) and incubated at 37 oc in a C0 2 incubator. Sera from immunized rhesus macaques were tested using serial twofold dilutions starting at 1:10 to 1 :640 or as required to reach an endpoint. The serum dilutions were mixed with each parental DENV serotype to obtain approximately 50 plaque forming units (PFU) per 0.2 ml, incubated at 37 oc for 30 min, then inoculated onto duplicate wells overlayered with nutrient agarose (EMEM, 2% FBS, 1% agarose). Plaques were visualized on day 6 by staining with 0.02% neutral red in Hank's balanced salt solution. The number of plaques reported for each serum dilution was the average of the duplicate wells. The percent reduction in plaques was calculated by comparison of the results obtained with control sera from unimmunized rhesus macaques. The neutralization titer was the rest serum dilution at which 50% plaque reduction occurred (PRNT 50 titer) determined by probit analysis.
Enzyme-linked immunosorbent assay
Antigen was prepared by centrifugation (27,000 rpm at 20 oC) of DENV-infected and -uninfected Vero cells for 2 h. Pellets were resuspended in PBS and pelleted again in 10% glycerol at 32,000 rpm for 2 hat 20 oc. Purified virions and control antigen were resuspended in PBS and stored at -20 oc until used. The analysis of sera from immunized rhesus macaques for DENV-2 antibodies was carried out as previously described (Simmons er al., 2006) . Briefly, microtiter plate wells were coated with purified DENV 2 virions in PBS at 4 oc overnight followed by blocking with 5% non-fat dry milk in PBS/0.01% Tween 20 for 1 h at 37 oc. Plates were then incubated with the test sera at twofold dilutions starting at 1:100 in blocking buffer for 1 hat 37 oc. The secondary antibody was peroxidase-conjugated goat antihuman lgG (Kirkegaard & Perry, Gaithersburg, MD) diluted in blocking solution and incubated for 1 h at 37 oc. The 2.2' azinodi [3ethyl benzthiazoline sulfonate (6)) (ABTS) peroxidase substrate system (Kirkegaard & Perry) was used ro visualize dengue virusspecific antibody. Assays were performed in duplicate with a positive and negative control on every plate. The net optical density (OD) values were determined by subtracting the absorbance of test serum with negative control antigen from the absorbance of test serum with the DENV antigen. Endpoint dilution titers were determined by the dilution at which the OD value was at ~0.10.
Preparation and administration of live attenuated virus (LAV) vacdnes
Production and testing of LA V vaccine candidates have previously been described in detail (Eckels et al., 2003; Sun et al., 2003 Sun et al., , 2009 . Briefly, the viruses were isolated from viremic sera from clinical DEN cases and attenuated by serial passage in primary dog kidney (PDK) cells, 6 to 50 PDK passages depending on the virus serotype and the vaccine formulation (Halstead and Marchette, 2003) . Following PDK passage, the vaccines were finished by three additional passages in diploid fetal rhesus lung-2 (FhRL 2) cells to produce the master and production seeds and the vaccines. The candidate monovalent vaccine viruses were tested individually and demonstrated to elicit significantly reduced viremia compared to the wild-type parental isolated when administered to rhesus monkeys (Eckels et al., 2003) . The monovalent LAV vaccines were formulated with excipients. 50 ,~.~g/ml neomycin sulfate. 5.5% lactose, and 1.9% human serum albumin as stabilizer, bottled, freeze dried, and stored at -20 C. Prior ro immunizations, each monovalent vaccine was rehydrated with sterile water for injection, and syringe mixed to produce tetravalent formulations, then administered to the animals by subcutaneous (SC) inoculation into the loose skin of the upper back at a dose of 5 log1o pfu per serotype.
The tetravalent LA V (TIA V) formulation used for the first rhesus experiment consisted ofDENV 1 (West Pac 74, 45AZS, PDK 20), DENV 2 (S16803, PDK 50), DENV 3 (CH53489, PDK 20), and DENV 4 (341750, PDK 6). The TLAV formulation for the second experiment was the same except that DENV 1 PDK 20 was replaced by DENV 1 PDK 27. This substitution was made necessary because the DENV 1 PDK 20 vaccine was re-derived by RNA transfection of FRhL cells and the re-derived vaccine was genetically less stable than the original DENV 1 PDK 20 vaccine used in the first experiment.
Preparation and administration of purified inactivated virus (PIV) vaccine
The TPIV vaccine was prepared from DENVs ( DENV 1 West Pac 74, DENV 2 S16803, DENV 3 CH53489, DENV 4 341750) propagated in Vero cells. For the second experiment. DENV 4 strain 341750 was substituted with strain TVP360 because TVP 360 was originally used for the PIV production seed based on its ability to reach higher titers in the Vero cell substrate. Virus in the culture supernatant was concentrated by tangential flow ultrafiltration using a 1 00-kDa screen channel membrane (Filtron, Inc.), purified by sucrose gradient ultracentrifugation, and inactivated with formalin as originally described (Putnak et al., 1996) . Monkeys were inoculated intramuscularly by needle and syringe in rhe upper arm (deltoid) with 4 JJg (1 J.Jg/serotype) of the TPIV formulation adjuvanted with 0.01% aluminum hydroxide (alum).
Preparation and administration of plasmid DNA vaccine
IDNA vaccines were prepared as previously described (Kochel er al.. 1997) . The vaccine constructs contained the DENV pre membrane (M) and full-length envelope (E) genes cloned into plasmid vector pVR1012 (Vical, San Diego, CA). The DENV 1 vaccine construct contained sequences from the Western Pacific 74 (West Pac 74) strain. whereas the plasmid constructs for DENVs 2, 3, and 4 contained sequences from near wild-type Philippine strains. The DENV 2 construct was modified by replacing the DENV transmembrane and cytoplasmic sequences with those of the mouse lysosome-associated membrane protein (LAMP) at the carboxy terminus of the E protein (D2MEL) (Raviprakash et al., 2001 (Raviprakash et al., . 2003 . Animals received 5 mg (1.25 mg/serotype) of TDNA vaccine per dose administered intramuscularly in the upper arm (deltoid), using the needle free Biojector system (Raviprakash et al., 2003) .
Animal immunizations and virus challenge
For the first experiment, 16 healthy, fJavivirus na"ive. Indian origin rhesus macaques (Macaca mulatta) were randomized into four groups (n=4 animal/group). Group 1 was primed with two doses of the IDNA vaccine on day -30 and day 0, group 2 was primed once with TPIV vaccine on day 0. and group 3 was primed once with the TLAV vaccine on day 0. Groups 1-3 were then boosted with TlA V vaccine on day 60. Group 4 served as a control group and received saline only on days 0 and 60. Six months after, the TLAV booster the animals were challenged with live near wild-type DENV 3 (CH53489) PDK 0.
For the second experiment, 32 healthy, flavivirus na'ive rhesus macaques were divided into two groups of 16 animals each. Sixteen animals received the TPIV vaccine on day 0 and the TLAV vaccine on day 60. The remaining 16 animals served as a control group and received saline on days 0 and 60. Six months after, the lasr immunization paired groups of four vaccinated and four control animals were challenged with each of the four dengue viruses. with one group challenged with DENV 1, another DENV-2, another DENV-3, and the final group receiving DENV-4. DENV challenges were administered by subcutaneous injection in the upper arm using 5 log 10 pfu of DENV 1 (West Pac 74), DENV 2 (S16803), DEN 3 (CH53489), or DEN 4 (341750), derived from wild-type virus isolates passaged only 3-4 times in Vera cells to make challenge virus stocks.
Viremia assay
The presence of virus in serum samples collected daily for 1 0 consecutive days after virus challenge was detected by incubation on Vera cell monolayers followed by immunofluorescent antibody (IFA) assay. Briefly, Vera 81 cells (ATCC) were propagated in 25 cm 2 flasks (T25) with EMEM. non-essential amino acids (BioWhittaker), 10% heat-inactivated FBS, and penicillin/streptomycin. Duplicate flasks were inoculated with 0.3 ml of a 1 :2 dilution of each post-challenge serum sample and incubated at 37 oc for 14 days, with a complete media change on day 7. Cells from each flask were harvested by scraping, washed with PBS, and spotted in duplicate onto immunonuorescence slides. DENV-infected cells were detected by staining with anti-DENV serotype-specific monoclonal antibodies as well as HMAF followed by ATC-conjugated goat anti-mouse lg. The cell fluorescence was scored as positive (+)or negative (-)compared to uninfected control cells.
Animal use statement
The research protocol using animals in this study was reviewed and approved by the Naval Medical Research Center's Animal Care and Use Committee according to the principles set forth in the Guide for the Care and Use of Laboratory Animal Research, Institute of Laboratory Animals. National Research Counsel. NIH Publication no. 92-3415.
